Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eszopiclone plus Bailemian for Parkinson's disease-related insomnia
ChiCTR2600123571Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Parkinson's disease (PD) and Insomnia comparing Control group (eszopiclone alone) with Bailemian combination group (Bailemian + eszopiclone) (2 arms). Primary endpoint: Wake after sleep onset (WASO) difference at week 4. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
eszopicloneBailemian capsules
03
Conditions
Parkinson's disease (PD)Insomnia
Beyond the preview
Go deeper on ChiCTR2600123571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123571.